Spinocerebellar ataxia

Feb 12, 2020

Global Bell's Palsy Incidence Assessment by Ethnicity & Geography, 2019-2029

Nov 07, 2019

Spinocerebellar Ataxia (SCA) Epidemiology Forecast to 2028: Assumptions and Rationale, Total Prevalent Population, Total Diagnosed Cases, Type-Specific Prevalence

Apr 05, 2019

Dystrogen Therapeutics Announces That Gene Therapy Successfully Cuts Off Production of Neuron-Destroying Protein in Huntington's Disease

Mar 14, 2019

Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole

Dec 05, 2017

Friedreich's Ataxia- Treatment Algorithm and Competitive Landscape 2017

Oct 17, 2017

Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies

Oct 02, 2017

Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial

Sep 11, 2017

Biohaven To Provide Development Program Update At The Morgan Stanley 15th Annual Global Healthcare Conference

Aug 07, 2017

Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017

Aug 03, 2017

Chondrial Announces FDA Orphan Drug Designation for CTI-1601, a Novel Investigational Technology for the Treatment of Friedreich's Ataxia

May 30, 2017

Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole